Late HCC onset after DAAs therapy in patients with SVR: a type D ADR that requires a longer follow-up?
Eur J Hosp Pharm
.
2019 Jul;26(4):243-244.
doi: 10.1136/ejhpharm-2019-001975.
Epub 2019 Jun 14.
Authors
Antonella Nappi
1
,
Alessandro Perrella
2
,
Luca Rinaldi
3
,
Antonio Izzi
4
,
Rodolfo Punzi
4
,
Luigi Elio Adinolfi
3
,
Costanza Sbeglia
2
,
Pasquale Bellopede
2
,
Adelaide Maddaloni
2
,
Nunzia Papa
1
,
Micaela Spatarella
1
Affiliations
1
HospitalPharmacy - Pharmacovigilance Unit, Ospedali dei Colli, P.O. D.Cotugno, Naples, Italy.
2
VII Unit InfectiousDiseaseand Immunology, Ospedali dei Colli P.O. D.Cotugno, Naples, Italy.
3
Gastroenterology Unit, Università degli Studi della Campania "LuigiVanvitelli", Naples, italy.
4
AORN Ospedali dei Colli, Napoli, Italy.
PMID:
31338185
PMCID:
PMC6613921
DOI:
10.1136/ejhpharm-2019-001975
No abstract available
Keywords:
ADR; DAAs; HCC; HCV; antiviral; cirrhosis.